OncoMatch/Clinical Trials/NCT06586957
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Is NCT06586957 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NKT3964 for solid tumor.
Treatment: NKT3964 — The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Ovarian Cancer
Endometrial Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Gastric Cancer
Small Cell Lung Cancer
Biomarker criteria
Required: CCNE1 amplification
CCNE1 amplification
Disease stage
Required: Stage III, IV
Prior therapy
Must have received: standard of care — advanced/metastatic
documented disease progression on last standard treatment
Cannot have received: CDK2 inhibitor
Prior investigative treatment with a selective or nonselective CDK2 inhibitor or degrader
Lab requirements
Blood counts
Kidney function
Liver function
Have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arkansas Medical School · Little Rock, Arkansas
- University of California - Los Angeles · Los Angeles, California
- UCSF · San Francisco, California
- SCRI at HealthOne · Denver, Colorado
- Florida Cancer Specialists & Research Institute · Lake Mary, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify